Landscapes / Companies

Swedish Orphan Biovitrum not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
5 approved
 
Next date
Pacritinib, Phase 2 trial completes
Drugs
5
in active trials · 10 in all
Trials
9 active
33 since 2021

Drugs5

DrugHow it worksPartnerStageNext dateDetails
Kinase inhibitor
CTI BioPharma
Approved 30 Dec 2026Phase 2 trial completes
—
Approved in the EU 15 Jan 2027Phase 3 trial completes
—
Approved 30 Jun 2028Phase 2/3 trial completes
Complement inhibitor
Apellis Pharmaceuticals
Approved 17 Jan 2031Phase 3 trial completes
Interleukin-1 receptor antagonist
Approved —

About

No active trial
NI-0501, Nitisinone, Recombinant coagulation factor, SEL-212, SOBI003
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow Swedish Orphan Biovitrum

Following is part of Solo: you see every change to Swedish Orphan Biovitrum the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in